

# Drug Policy:

## Ibrance™ (palbociclib)

<b>POLICY NUMBER</b> UM ONC_1272	<b>SUBJECT</b> Ibrance™ (palbociclib)		<b>DEPT/PROGRAM</b> UM Dept	<b>PAGE 1 of 3</b>
<b>DATES COMMITTEE REVIEWED</b> 03/27/15, 05/24/16, 07/26/17, 07/19/18, 06/13/19, 12/11/19, 03/11/20, 09/11/20, 01/13/21, 05/12/21, 09/08/21, 11/15/21, 02/09/22, 05/11/22, 08/10/22, 06/14/23, 06/12/24	<b>APPROVAL DATE</b> June 12, 2024	<b>EFFECTIVE DATE</b> June 28, 2024	<b>COMMITTEE APPROVAL DATES</b> 03/27/15, 05/24/16, 07/26/17, 07/19/18, 06/13/19, 12/11/19, 03/11/20, 09/11/20, 01/13/21, 05/12/21, 09/08/21, 11/15/21, 02/09/22, 05/11/22, 08/10/22, 06/14/23, 06/12/24	
<b>PRIMARY BUSINESS OWNER:</b> UM		<b>COMMITTEE/BOARD APPROVAL</b> Utilization Management Committee		
<b>NCQA STANDARDS</b> UM 2		<b>ADDITIONAL AREAS OF IMPACT</b>		
<b>CMS REQUIREMENTS</b>	<b>STATE/FEDERAL REQUIREMENTS</b>		<b>APPLICABLE LINES OF BUSINESS</b> Commercial, Exchange, Medicaid	

### I. PURPOSE

To define and describe the accepted indications for Ibrance (palbociclib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolut is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolut may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

### II. INDICATIONS FOR USE/INCLUSION CRITERIA

#### A. Continuation requests for a not-approvable medication shall be exempt from this Evolut policy provided:

1. The requested medication was used within the last year, **AND**
2. The member has not experienced disease progression and/or no intolerance to the requested medication, **AND**
3. Additional medication(s) are not being added to the continuation request.

#### B. Breast Cancer

1. Ibrance (palbociclib) may be used in members with ER/PR positive and HER2 negative recurrent unresectable or metastatic breast cancer as follows:

- a. In combination with an aromatase inhibitor [i.e., Arimidex (anastrozole), Femara (letrozole), Aromasin (exemestane)] in postmenopausal/premenopausal women treated with ovarian ablation/suppression as first line therapy **OR**
- b. In combination with fulvestrant in postmenopausal/premenopausal women treated with ovarian ablation/suppression as subsequent therapy, if CDK4/6 inhibitor [e.g., Kisqali (ribociclib), Verzenio (abemaciclib)] was not previously used.

### III. EXCLUSION CRITERIA

- A. Disease progression while taking Ibrance (palbociclib) **OR** another CDK4/6 inhibitor [e.g., Kisqali (ribociclib) or Verzenio (abemaciclib)].
- B. Dosing exceeds single dose limit of Ibrance (palbociclib) 125 mg.
- C. Treatment exceeds the maximum limit of 21 (125 mg, 100 mg, or 75 mg) capsules/month.
- D. Investigational use of Ibrance (palbociclib) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  - 1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  - 2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  - 3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
  - 4. Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
  - 5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
  - 6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
  - 7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

### IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

### V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

### VI. ATTACHMENTS

A. None

## VII. REFERENCES

- A. Cristofanilli et al. Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. *Journal of Clinical Oncology* 2021 39:15\_suppl, 1000-1000.
- B. Slamon DJ, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. *J Clin Oncol*. 2018 Aug 20;36(24):2465-2472.
- C. Goetz MP, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. *J Clin Oncol*. 2017 Nov 10;35(32):3638-3646.
- D. Sledge GW Jr, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. *J Clin Oncol*. 2017 Sep 1;35(25):2875-2884.
- E. Turner NC, et al. PALOMA-3 Trial. Overall survival with palbociclib and fulvestrant in advanced breast cancer. *N Engl J Med* 2018;379:1926-36.
- F. Ibrance prescribing information. Pfizer Laboratories Div Pfizer, Inc. NY, NY. 2022.
- G. *Clinical Pharmacology Elsevier Gold Standard* 2023.
- H. *Micromedex® Healthcare Series: Micromedex Drugdex* Ann Arbor, Michigan 2023.
- I. National Comprehensive Cancer Network. *Cancer Guidelines and Drugs and Biologics Compendium* 2023.
- J. *AHFS Drug Information*. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2023.
- K. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
- L. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.